Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Philippe Moreau; Niels W.C.J. van de Donk; Jesús F. San Miguel; Henk M. Lokhorst; Hareth Nahi; Dina Ben‐Yehuda; Michèle Cavo; Gordon Cook; Michel Delforge; Hermann Einsele; Sonja Zweegman; Heinz Ludwig; Christoph Driessen; Antonio Palumbo; Thierry Façon; Torben Plesner; Meletios A Dimopoulos; Pia Sondergeld; Pieter Sonneveld; María‐Victoria Mateos

doi:10.1007/s40265-016-0573-4

Corrigendum2016

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Philippe Moreau, Niels W.C.J. van de Donk, Jesús F. San Miguel, Henk M. Lokhorst, Hareth Nahi, Dina Ben‐Yehuda, Michèle Cavo, Gordon Cook, Michel Delforge, Hermann Einsele, Sonja Zweegman, Heinz Ludwig, Christoph Driessen, Antonio Palumbo, Thierry Façon, Torben Plesner, Meletios A Dimopoulos, Pia Sondergeld, Pieter Sonneveld, María‐Victoria Mateos

Article2016

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)

Philippe Moreau, Niels W.C.J. van de Donk, Jesús F. San Miguel, Henk M. Lokhorst, Hareth Nahi, Dina Ben‐Yehuda, Michèle Cavo, Gordon Cook, Michel Delforge, Hermann Einsele, Sonja Zweegman, Heinz Ludwig, Christoph Driessen, Antonio Palumbo, Thierry Façon, Torben Plesner, Meletios A Dimopoulos, Pia Sondergeld, Pieter Sonneveld, María‐Victoria Mateos

Article2016

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)

Philippe Moreau, Niels W.C.J. van de Donk, Jesús F. San Miguel, Henk M. Lokhorst, Hareth Nahi, Dina Ben‐Yehuda, Michèle Cavo, Gordon Cook, Michel Delforge, Hermann Einsele, Sonja Zweegman, Heinz Ludwig, Christoph Driessen, Antonio Palumbo, Thierry Façon, Torben Plesner, Meletios A Dimopoulos, Pia Sondergeld, Pieter Sonneveld, María‐Victoria Mateos

Article2025

Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Vassilis Koutoulidis, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Letter2017

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Dimitrios C. Ziogas, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Despina Fotiou, Μαρία Ρούσσου, Nikolaos Kanellias, Ioanna Tatouli, Evangelos Eleutherakis‐Papaiakovou, Ioannis Panagiotidis, Ioannis Ntanasis‐Stathopoulos, Efstathios Kastritis, Meletios A Dimopoulos

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Discussion(0)

Related publications

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)

Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases